Decreasing cancer risk associated with inflammatory bowel disease

Inflammatory bowel disease is caused by chronic inflammation , which leads to damage of the intestinal epithelium.

Patients with have an elevated risk for developing colorectal cancer because of this .

In an effort to develop strategies to break the cycle of inflammation, Dr. Brent Polk and colleagues at the University of Southern California in Los Angeles examined two mouse models of colorectal cancer.

Their work shows that inactivating a key receptor, known as epidermal growth factor receptor, increases the frequency and severity of colorectal tumors.

Though epidermal growth factor has well-defined roles in promoting tumor growth, the Polk team now finds that epidermal growth factor receptor can ameliorate the response to chronic inflammation and reduces tumor development by fine-tuning inflammation and the generation of intestinal epithelium.

Their results suggest that promoting epidermal growth factor activity in patients with inflammatory bowel disease could decrease long-term by reducing inflammation.

More information: View this article at: www.jci.org/articles/view/6288… ab673ae8215aaf449677

add to favorites email to friend print save as pdf

Related Stories

2 immune-system proteins linked to colitis-associated cancer

Feb 02, 2009

Recent research from the laboratory of Michael Karin, PhD, at the University of California, San Diego School of Medicine - the first researcher to demonstrate a molecular link between inflammation and cancer - has identified ...

First step to new therapy for chronic bowel disease

Jul 06, 2010

Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University (UGent) have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. ...

Recommended for you

Phthalates heighten risk for childhood asthma

Sep 17, 2014

Researchers at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health are the first to demonstrate an association between childhood asthma and prenatal exposure to two phthalates used ...

ERS: Mepolizumab is glucocorticoid-sparing in asthma

Sep 09, 2014

(HealthDay)—For patients with eosinophilic asthma, mepolizumab has a glucocorticoid-sparing effect and reduces exacerbations when administered intravenously or subcutaneously, according to two studies published ...

User comments